Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model

Brain Research

Volumn 776, Issue 1-2, 1997, Pages 88-95

  Lekieffre, Delphine ^a   Benavides, Jesus ^a   Scatton, Bernard ^a   Nowicki, Jean Pierre ^a  

^a SANOFI   (France)

Author keywords

Eliprodil; Neuroprotection; Rt PA; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; ELIPRODIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE; THROMBOEMBOLISM;

ANIMALS; BRAIN ISCHEMIA; CEREBRAL INFARCTION; CEREBROVASCULAR DISORDERS; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HEMOSTASIS; MALE; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; PARTIAL THROMBOPLASTIN TIME; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0031474759     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00992-X     Document Type: Article

References (24)

1. Bowes M.P., Zivin J.A., Rothlein R. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp. Neurol. 119:1993;215-219.
2. Choi D.W. Calcium mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci. 11:1988;465-469.
3. Duverger D., MacKenzie E.T. The quantification of cerebral infarction following focal ischemia in the rat: influence of strain, arterial pressure, blood glucose concentration, and age. J. Cereb. Blood Flow Metabol. 8:1988;449-461.
4. Duverger D., Scatton B., Benavides J., Nowicki J.P. Neuroprotective effect of eliprodil after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 15:1995;S369.
5. Fears R. Biochemical pharmacology and therapeutic aspects of thrombolytic agents. Pharmacol. Rev. 42:1990;201-222.
6. Fieschi C., Argentino C., Lenzi G.L., Sacchetti M.L., Toni D., Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J. Neurol. Sci. 91:1989;311-322.
7. Fisher M., Bogousslavsky J. Evolving toward effective therapy for acute ischemic stroke. J.Am. Med. Assoc. 270:1993;360-364.
8. Gotti B., Duverger D., Bertin J., Carter C., Dupont R., Frost J., Gaudillière B., MacKenzie E.T., Rousseau J., Scatton B., Wick A. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia J. Pharmacol. Exp. Ther. 247:1988;1211-1221.
9. Lee B.C.P., Brock J.M., Fan T., Seibert A., Moonen C., Kissel P., Chehrazi B., Bradbury E.M. 31P spectroscopy in thrombolytic treatment of experimental cerebral infarct. AJR Am. J. Roentgenol. 152:1989;623-628.
10. Meden P., Overgaard K., Pedersen H., Boysen G. Effect of early treatment with Tirilazad (U74006F) combined with delayed thrombolytic therapy in rat embolic stroke. Cerebrovasc. Dis. 6:1996;141-148.
11. N.I.N.D.S. Tissue plasminogen activator for acute ischemic stroke. New Engl. J. Med. 333:1995;1581-1587.
12. Overgaard K., Sereghy T., Boysen G., Pedersen H., Diemer N.H. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model. Stroke. 23:1992;1167-1174.
13. Overgaard K., Sereghy T., Pedersen H., Boysen G. Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke. Neurol. Res. 15:1993;344-349.
14. Overgaard K. Thrombolytic therapy in experimental embolic stroke. Cerebrovasc. Brain Metab. Rev. 6:1994;257-286.
15. Overgaard K., Sereghy T., Pedersen H., Boysen G. Effect of delayed thrombolysis with rt-PA in a rat embolic stroke model. J. Cereb. Blood Flow Metab. 14:1994;472-477.
16. Papadopoulos S.M., Chandler W.F., Salamat M.S., Topol E.J., Sackellares J.C. Recombinant tissue-type plasminogen activator therapy in acute thromboembolic stroke. J. Neurosurg. 67:1987;394-398.
17. Scatton B. Excitatory amino acid receptor antagonists: a novel treatment for ischemic cerebrovascular diseases. Life Sci. 55(25/26):1994;2115-2124.
18. Scatton B., Giroux C., Thénot J.P., Frost J., George P., Carter C., Benavides J. Eliprodil. Drugs Future. 19(10):1994;905-909.
19. Sereghy T., Overgaard K., Boysen G. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke. 24:1993;1702-1708.
20. Shalaby I.A., Chenard B.L., Prochniak M.A., Butler T.W. The neuroprotective effects of the N-methyl-D-aspartate receptor antagonists ifenprodil and SL 82.0715 on hippocampal cells in culture. J. Pharmacol. Exp. Ther. 260:1991;925-945.
21. Toulmond S., Serrano A., Benavides J., Scatton B. Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window. Brain Res. 620:1993;32-41.
22. Zivin J.A., Fisher M., DeGirolami U., Hemenway C.C., Stashak J.A. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science. 230:1985;1289-1292.
23. Zivin J.A., Mazzarella V. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch. Neurol. 48:1991;1235-1238.
24. Zivin J.A. Reperfusion injury: treatment after thrombolysis. Cerebrovasc. Dis. 6:1996;175-194.